Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Regeneron Pharmaceuticals sells several FDA-approved drugs. Photo: Regeneron
George Yancopoulos, the president and top scientist at Regeneron Pharmaceuticals, took home approximately $268 million in 2017, based on calculations of his actual realized stock gains disclosed in a new federal filing.
The big picture: That's the largest pay package of any health care executive from 2017 so far. Yancopoulos, who is the main inventor of Regeneron's prescription drugs like Eylea and Praluent, made almost three times as much as Regeneron's CEO, Leonard Schleifer, who made $95 million last year.